BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cui G, Martin RC, Jin H, Liu X, Pandit H, Zhao H, Cai L, Zhang P, Li W, Li Y. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver. J Exp Clin Cancer Res. 2018;37:136. [PMID: 29973237 DOI: 10.1186/s13046-018-0781-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Li M, Yu L, Zhai Q, Liu B, Zhao J, Chen W, Tian F. Ganoderma lucidum Ethanol Extraction Promotes Dextran Sulphate Sodium Induced Colitis Recovery and Modulation in Microbiota. Foods 2022;11. [PMID: 36553765 DOI: 10.3390/foods11244023] [Reference Citation Analysis]
2 Leung RWH, Lee TKW. Wnt/β-Catenin Signaling as a Driver of Stemness and Metabolic Reprogramming in Hepatocellular Carcinoma. Cancers 2022;14:5468. [DOI: 10.3390/cancers14215468] [Reference Citation Analysis]
3 Song L, Wang L, Hou Y, Zhou J, Chen C, Ye X, Dong W, Gao H, Liu Y, Qiao G, Pan T, Chen Q, Cao Y, Hu F, Rao Z, Chen Y, Han Y, Zheng M, Luo Y, Li X, Chen Y, Huang Z. FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axis. Hepatology 2022;76:1105-20. [PMID: 35152446 DOI: 10.1002/hep.32404] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
4 Vitale G, Mattiaccio A, Conti A, Turco L, Seri M, Piscaglia F, Morelli MC. Genetics in Familial Intrahepatic Cholestasis: Clinical Patterns and Development of Liver and Biliary Cancers: A Review of the Literature. Cancers 2022;14:3421. [DOI: 10.3390/cancers14143421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sangineto M, Grander C, Grabherr F, Mayr L, Enrich B, Schwärzler J, Dallio M, Bukke VN, Moola A, Moschetta A, Adolph TE, Sabbà C, Serviddio G, Tilg H. Recovery of Bacteroides thetaiotaomicron ameliorates hepatic steatosis in experimental alcohol-related liver disease. Gut Microbes 2022;14:2089006. [PMID: 35786161 DOI: 10.1080/19490976.2022.2089006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Mohamed GA, Nashaat EH, Fawzy HM, ElGhandour AM. Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma. World J Hepatol 2022;14:623-33. [PMID: 35582295 DOI: 10.4254/wjh.v14.i3.623] [Reference Citation Analysis]
7 Gu CY, Lee TKW. Preclinical mouse models of hepatocellular carcinoma: An overview and update. Experimental Cell Research 2022. [DOI: 10.1016/j.yexcr.2022.113042] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Tomonari T, Sato Y, Tanaka H, Mitsuhashi T, Hirao A, Tanaka T, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Takayama T. Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. JGH Open 2021;5:1275-83. [PMID: 34816013 DOI: 10.1002/jgh3.12663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Yang C, Wan M, Xu D, Pan D, Xia H, Yang L, Sun G. Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut-Liver Axis. Int J Mol Sci 2021;22:10858. [PMID: 34639207 DOI: 10.3390/ijms221910858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yu Y, Shi X, Zheng Q, Wang X, Liu X, Tan M, Lv G, Zhang P, Martin RC, Li Y. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice. Int J Biol Sci 2021;17:2576-89. [PMID: 34326695 DOI: 10.7150/ijbs.58776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Sydor S, Best J, Messerschmidt I, Manka P, Vilchez-Vargas R, Brodesser S, Lucas C, Wegehaupt A, Wenning C, Aßmuth S, Hohenester S, Link A, Faber KN, Moshage H, Cubero FJ, Friedman SL, Gerken G, Trauner M, Canbay A, Bechmann LP. Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC. Clin Transl Gastroenterol 2020;11:e00131. [PMID: 32352707 DOI: 10.14309/ctg.0000000000000131] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 19.0] [Reference Citation Analysis]
12 Chen Z, Jiang L, Liang L, Koral K, Zhang Q, Zhao L, Lu S, Tao J. The Role of Fibroblast Growth Factor 19 in Hepatocellular Carcinoma. Am J Pathol 2021;191:1180-92. [PMID: 34000282 DOI: 10.1016/j.ajpath.2021.04.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Ferguson HR, Smith MP, Francavilla C. Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling. Cells 2021;10. [PMID: 34068954 DOI: 10.3390/cells10051201] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 12.5] [Reference Citation Analysis]
14 Jiang L, Zhang H, Xiao D, Wei H, Chen Y. Farnesoid X receptor (FXR): Structures and ligands. Comput Struct Biotechnol J 2021;19:2148-59. [PMID: 33995909 DOI: 10.1016/j.csbj.2021.04.029] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
15 Wang H, Yang J, Zhang K, Liu J, Li Y, Su W, Song N. Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets. Front Pharmacol 2021;12:650388. [PMID: 33935756 DOI: 10.3389/fphar.2021.650388] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 Tong Y, Gao H, Qi Q, Liu X, Li J, Gao J, Li P, Wang Y, Du L, Wang C. High fat diet, gut microbiome and gastrointestinal cancer. Theranostics 2021;11:5889-910. [PMID: 33897888 DOI: 10.7150/thno.56157] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
17 Prawira A, Le TBU, Vu TC, Huynh H. Ribociclib enhances infigratinib-induced cancer cell differentiation and delays resistance in FGFR-driven hepatocellular carcinoma. Liver Int 2021;41:608-20. [PMID: 33179425 DOI: 10.1111/liv.14728] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
18 Akdeniz Odemis D, Tuncer SB, Adamnejad Ghafour A, Jabbarli K, Gider Y, Celik B, Kuru Turkcan G, Sukruoglu Erdogan O, Kilic Erciyas S, Avsar M, Kebudi R, Buyukkapu Bay S, Tuncer S, Yazici H. FGFR4 c.1162G > A (p.Gly388Arg) Polymorphism Analysis in Turkish Patients with Retinoblastoma. J Oncol 2020;2020:9401038. [PMID: 33456465 DOI: 10.1155/2020/9401038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Zheng Q, Martin RC, Shi X, Pandit H, Yu Y, Liu X, Guo W, Tan M, Bai O, Meng X, Li Y. Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling. Theranostics 2020;10:9923-36. [PMID: 32929325 DOI: 10.7150/thno.45988] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
20 Manieri E, Folgueira C, Rodríguez ME, Leiva-Vega L, Esteban-Lafuente L, Chen C, Cubero FJ, Barrett T, Cavanagh-Kyros J, Seruggia D, Rosell A, Sanchez-Cabo F, Gómez MJ, Monte MJ, G Marin JJ, Davis RJ, Mora A, Sabio G. JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma. Proc Natl Acad Sci U S A 2020;117:16492-9. [PMID: 32601222 DOI: 10.1073/pnas.2002672117] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
21 Pandit H, Li Y, Zheng Q, Guo W, Yu Y, Li S, Martin RCG. Carcinogenetic initiation contributed by EpCAM+ cancer cells in orthotopic HCC models of immunocompetent and athymic mice. Oncotarget 2020;11:2047-60. [PMID: 32547703 DOI: 10.18632/oncotarget.27454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
22 Yun Ji, Yue Yin, Lijun Sun, Weizhen Zhang. The Molecular and Mechanistic Insights Based on Gut–Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement. Int J Mol Sci 2020;21:3066. [PMID: 32357561 DOI: 10.3390/ijms21093066] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 13.3] [Reference Citation Analysis]
23 Sun Y, Zhu M, Zhao H, Ni X, Chang R, Su J, Huang H, Cui S, Wang X, Yuan J, Yuan J, OuYang R, Zhang R, Chen W, Gu Y, Sun Y. Serum Fibroblast Growth Factor 19 and Total Bile Acid Concentrations Are Potential Biomarkers of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus. Biomed Res Int 2020;2020:1751989. [PMID: 32104677 DOI: 10.1155/2020/1751989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 Ocker M. Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma. World J Gastroenterol 2020; 26(3): 279-290 [PMID: 31988589 DOI: 10.3748/wjg.v26.i3.279] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
25 Manieri E, Esteban-lafuente L, Rodríguez ME, Leiva-vega L, Chen C, Cubero FJ, Barrett T, Cavanagh-kyros J, Seruggia D, Monte MJ, Marin JJ, Davis RJ, Mora A, Sabio G. Hepatic JNK-mediated bile acid homeostasis regulates liver cancer through PPARα.. [DOI: 10.1101/783761] [Reference Citation Analysis]
26 Raja A, Park I, Haq F, Ahn SM. FGF19-FGFR4 Signaling in Hepatocellular Carcinoma. Cells. 2019;8:pii: E536. [PMID: 31167419 DOI: 10.3390/cells8060536] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 15.3] [Reference Citation Analysis]
27 Yu X, Yan N, Li Z, Hua Y, Chen W. FGF19 sustains the high proliferative ability of keratinocytes in psoriasis through the regulation of Wnt/GSK-3β/β-catenin signalling via FGFR4. Clin Exp Pharmacol Physiol 2019;46:761-9. [PMID: 31074061 DOI: 10.1111/1440-1681.13103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
28 Wang J, Fu T, Dong R, Wang C, Liu K, Sun H, Huo X, Ma X, Yang X, Meng Q. Hepatoprotection of auraptene from the peels of citrus fruits against 17α-ethinylestradiol-induced cholestasis in mice by activating farnesoid X receptor. Food Funct 2019;10:3839-50. [DOI: 10.1039/c9fo00318e] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
29 van Zutphen T, Bertolini A, de Vries HD, Bloks VW, de Boer JF, Jonker JW, Kuipers F. Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease. Bile Acids and Their Receptors 2019. [DOI: 10.1007/164_2019_233] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]